MX2024009650A - Sal cristalina y formas de solvato de murizatoclax (amg 397). - Google Patents
Sal cristalina y formas de solvato de murizatoclax (amg 397).Info
- Publication number
- MX2024009650A MX2024009650A MX2024009650A MX2024009650A MX2024009650A MX 2024009650 A MX2024009650 A MX 2024009650A MX 2024009650 A MX2024009650 A MX 2024009650A MX 2024009650 A MX2024009650 A MX 2024009650A MX 2024009650 A MX2024009650 A MX 2024009650A
- Authority
- MX
- Mexico
- Prior art keywords
- solvate forms
- amg
- salt
- murizatoclax
- crystalline salt
- Prior art date
Links
- 150000003839 salts Chemical group 0.000 title abstract 5
- 239000012453 solvate Chemical group 0.000 title abstract 5
- BJTFTQIBRVBSBH-VCQPVEJUSA-N CO[C@]1(CN2CCN3CCCC[C@@H]3C2)\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2=CC3=C(OC[C@]4(CCCC5=C4C=CC(Cl)=C5)CN3C[C@@H]3CC[C@@H]13)C=C2 Chemical compound CO[C@]1(CN2CCN3CCCC[C@@H]3C2)\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2=CC3=C(OC[C@]4(CCCC5=C4C=CC(Cl)=C5)CN3C[C@@H]3CC[C@@H]13)C=C2 BJTFTQIBRVBSBH-VCQPVEJUSA-N 0.000 title abstract 3
- BJTFTQIBRVBSBH-MUHQWPPJSA-N murizatoclax Chemical compound [H][C@]12CC[C@@H]1CN1C[C@@]3(CCCC4=CC(Cl)=CC=C34)COC3=C1C=C(C=C3)C(=O)NS(=O)(=O)[C@@H](C)[C@H](C)C\C=C\[C@@]2(CN1CCN2CCCC[C@]2([H])C1)OC BJTFTQIBRVBSBH-MUHQWPPJSA-N 0.000 title 1
- 229940071537 murizatoclax Drugs 0.000 title 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 abstract 2
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263306781P | 2022-02-04 | 2022-02-04 | |
| PCT/US2023/012252 WO2023150250A1 (en) | 2022-02-04 | 2023-02-03 | Crystalline salt and solvate forms of murizatoclax (amg 397) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009650A true MX2024009650A (es) | 2024-08-14 |
Family
ID=86054183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009650A MX2024009650A (es) | 2022-02-04 | 2023-02-03 | Sal cristalina y formas de solvato de murizatoclax (amg 397). |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250122224A1 (enExample) |
| EP (1) | EP4472985A1 (enExample) |
| JP (1) | JP2025505142A (enExample) |
| AU (1) | AU2023215171A1 (enExample) |
| CA (1) | CA3248348A1 (enExample) |
| MX (1) | MX2024009650A (enExample) |
| WO (1) | WO2023150250A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4519271A1 (en) | 2022-05-04 | 2025-03-12 | Gilead Sciences, Inc. | Salts and polymorphs of certain mcl-1 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8576985B2 (en) | 2009-09-01 | 2013-11-05 | Aptuit (West Lafayette) Llc | Methods for indexing solid forms of compounds |
| JP6453507B2 (ja) * | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| JP2021161114A (ja) * | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Ｍｃｌ−１化合物のメチル化 |
-
2023
- 2023-02-03 WO PCT/US2023/012252 patent/WO2023150250A1/en not_active Ceased
- 2023-02-03 US US18/730,353 patent/US20250122224A1/en active Pending
- 2023-02-03 JP JP2024545809A patent/JP2025505142A/ja active Pending
- 2023-02-03 MX MX2024009650A patent/MX2024009650A/es unknown
- 2023-02-03 AU AU2023215171A patent/AU2023215171A1/en active Pending
- 2023-02-03 CA CA3248348A patent/CA3248348A1/en active Pending
- 2023-02-03 EP EP23718377.7A patent/EP4472985A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023215171A1 (en) | 2024-07-04 |
| JP2025505142A (ja) | 2025-02-21 |
| US20250122224A1 (en) | 2025-04-17 |
| EP4472985A1 (en) | 2024-12-11 |
| CA3248348A1 (en) | 2023-08-10 |
| WO2023150250A1 (en) | 2023-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024009650A (es) | Sal cristalina y formas de solvato de murizatoclax (amg 397). | |
| CO2021014022A2 (es) | Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona | |
| EP4647129A3 (en) | PROCESS FOR PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A!PYRROLO[2,3-E!PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID FORMS THEREIN | |
| UY27380A1 (es) | Compuestos de heteroarilo bicíclicos fusionados sustituidos con heteroarilo como ligandos del receptor gabaa | |
| HUT74679A (en) | K-252a indolocarbazole alkaloid derivatives which enhance neurotrophin-induced activity | |
| EA201500654A1 (ru) | Терапевтически активные производные пиразолопиримидина | |
| ES2178668T3 (es) | Naftilamidas como agentes del sistema nervioso central. | |
| EE9900079A (et) | Meetod 21-atsüüloksüpregna-1,4-dieen-11ß,16a,17a-triool-3,20-diooni derivaatide 16,17-atsetaalderivaatide R-epimeerseks rikastamiseks | |
| ES2078405T3 (es) | Procedimiento para la purificacion de insulinas por cromatografia. | |
| MX2024009448A (es) | Formas cristalinas de un inhibidor de mcl-1. | |
| UY25501A1 (es) | Procedimiento para la preparacion de (s,s)-bencil-2,8-diazabiciclo [4.3.0]nonano | |
| UA100835C2 (ru) | СПОСОБ СИНТЕЗА (3R,3aS,6aR)-ГЕКСАГИДРОФУРО[2,3-b]ФУРАН-3-ОЛА, ПРОМЕЖУТОЧНОЕ СОЕДИНЕНИЕ И СПОСОБ ЕГО ПОЛУЧЕНИЯ | |
| AR112788A1 (es) | Compuesto pentacíclico | |
| CL2009001158A1 (es) | Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer. | |
| MX2025015400A (es) | Moduladores positivos del receptor de acetilcolina muscarinico m4 | |
| YU30302A (sh) | Supstituisani norbornilamino-derivati, postupak za njihovu proizvodnju, njihova primena u svojstvu leka ili dijagnostičkog reagensa kao i lekovi koji sadrže jedinjenja | |
| Norambuena et al. | Language, analogical reasoning, and working memory skills in emergent literacy period: Typical and DLD trajectories via Cluster Analyses | |
| GB737693A (en) | Improvements relating to jigs and fixtures | |
| Xiao et al. | Purification and characterization of Hainantoxin-V, a tetrodotoxin-sensitive sodium channel inhibitor from the venom of the spider Selenocosmia hainana | |
| MX2024012192A (es) | Formas de sal y solvatos de antagonistas de mci-1 | |
| Arie et al. | Developmental changes in the regulation of calcium-dependent neurite outgrowth | |
| BR112021025786A2 (pt) | Polimorfos de um inibidor de quinase macrocíclico | |
| Wang et al. | Discovery of two P-superfamily conotoxins, lt9a and lt9b, with different modifications on voltage-sensitive sodium channels | |
| Perovic et al. | Navigating narratives: unpacking strengths and weaknesses in the macrostructure of Croatian-speaking children with Williams syndrome | |
| Lenhart et al. | The Impact of Varying Exercise Protocols on Neurogenesis and Angiogenesis in the Dentate Gyrus |